Search

Displaying results 561 - 570 of 10000 in total
  1. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea … [L32813] Vildagliptin is currently under investigation in the US.

    Mixtures: VILDAGLIPTIN E METFORMINA SANDOZ, VILDAGLIPTIN E METFORMINA SANDOZCategories: Drugs Used in Diabetes
  2. Drug

    Tamoxifen

    go.drugbank.com/drugs/DB00675
    ApprovedInvestigational

    [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments. … [A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799]

    Synonyms: 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamineProducts: TAMOXIFENE EG
  3. Drug

    Petrolatum

    go.drugbank.com/drugs/DB11058
    ApprovedInvestigational

    It is used as an ointment base, topical protectant, and lubricant.

    Mixtures: Veradex-E, Ea Eight Hr Lip Sheer TintsCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Indomethacin

    go.drugbank.com/drugs/DB00328
    ApprovedInvestigational

    Although deemed effective in reducing ocular inflammation in clinical studies, topical NSAIDs were also associated with a potential reduction in corneal sensitivity accompanied by an increased risk of … Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, [A486] along with other acetic acid derivatives such as [diclofenac]

    Products: Indomethacin ER
  5. Target

    Chain A, Red Copper Protein Nitrosocyanin

    go.drugbank.com/bio_entities/BE0002711
    TargetNitrosomonas europaea (strain ATCC 19718 / NBRC 14298)

    Polypeptides: Chain A, Red Copper Protein Nitrosocyanin
  6. Target

    Cytochrome b6-f complex subunit 7

    go.drugbank.com/bio_entities/BE0003908
    TargetMastigocladus laminosus

    Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.

    Polypeptides: Cytochrome b6-f complex subunit 7Synonyms: Cytochrome b6-f complex subunit PetM, Cytochrome b6-f complex subunit VII
  7. Target

    Cytochrome b6-f complex subunit 8

    go.drugbank.com/bio_entities/BE0003909
    TargetMastigocladus laminosus

    Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.

    Polypeptides: Cytochrome b6-f complex subunit 8Synonyms: Cytochrome b6-f complex subunit PetN, Cytochrome b6-f complex subunit VIII
  8. Target

    Trafficking protein particle complex subunit 6A

    go.drugbank.com/bio_entities/BE0004275
    TargetHumans

    May play a role in vesicular transport during the biogenesis of melanosomes

    Polypeptides: Trafficking protein particle complex subunit 6ASynonyms: TRAPP complex subunit 6A
  9. Target

    Trafficking protein particle complex subunit 5

    go.drugbank.com/bio_entities/BE0004277
    TargetHumans

    May play a role in vesicular transport from endoplasmic reticulum to Golgi

    Polypeptides: Trafficking protein particle complex subunit 5
  10. Target

    Nuclear factor NF-kappa-B complex

    go.drugbank.com/bio_entities/BE0009554
    TargetHumans

    The heterodimeric RELA-NFKB1 complex appears to be most abundant one. … NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to